Trial Profile
Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs IRX 2 (Primary) ; Nivolumab (Primary) ; Cyclophosphamide
- Indications Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Aug 2019 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
- 26 Aug 2019 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.
- 26 Aug 2019 Planned initiation date changed from 1 Jul 2019 to 1 Jul 2020.